Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.

European journal of cancer (Oxford, England : 1990) - 1 Feb 2016

Bournet Barbara, Buscail Camille, Muscari Fabrice, Cordelier Pierre, Buscail Louis

Abstract excerpt

Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple cellular processes, such as transformation, proliferation, invasion, and survival are activated. The aim of this review was to present all potential clinical applications of targeting KRAS in terms of diagnosis and management of pancreatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Diagnosis, Differential

Share to Endoscopic Ultrasound-Guided Fine Needle Aspiration

Share to Molecular Targeted Therapy

Share to Pancreatic Neoplasms

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 26735353
DOI: 10.1016/j.ejca.2015.11.012

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.PMID 26735353Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.Semantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

Challenges in Ras therapeutics in pancreatic cancer.Semantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Emerging role of the KRAS-PDK1 axis in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.